SOPHiA GENETICS (SOPH) vs. Its Competitors Head-To-Head Contrast

SOPHiA GENETICS (NASDAQ:SOPH) is one of 93 public companies in the “Healthcare Technology” industry, but how does it contrast to its competitors? We will compare SOPHiA GENETICS to similar companies based on the strength of its risk, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Risk and Volatility

SOPHiA GENETICS has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS’s competitors have a beta of 1.11, meaning that their average share price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for SOPHiA GENETICS and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1	1	3	0	2.40
SOPHiA GENETICS Competitors	455	1536	2751	89	2.51

SOPHiA GENETICS currently has a consensus price target of $10.00, indicating a potential upside of 28.06%. As a group, “Healthcare Technology” companies have a potential upside of 43.18%. Given SOPHiA GENETICS’s competitors stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS has less favorable growth aspects than its competitors.

Profitability

This table compares SOPHiA GENETICS and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-89.18%	-128.69%	-44.73%
SOPHiA GENETICS Competitors	-751.01%	-29.51%	-15.37%

Earnings and Valuation

This table compares SOPHiA GENETICS and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
SOPHiA GENETICS	$77.27 million	-$79.00 million	-7.16
SOPHiA GENETICS Competitors	$342.20 million	-$24.15 million	12.84

SOPHiA GENETICS’s competitors have higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 42.4% of shares of all “Healthcare Technology” companies are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 16.2% of shares of all “Healthcare Technology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

SOPHiA GENETICS competitors beat SOPHiA GENETICS on 11 of the 13 factors compared.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.